The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Researchers at NYU Tandon School of Engineering have developed a new method for creating microscopic drug delivery capsules ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

AstraZeneca, Pfizer and other multinational drug companies have spent a record amount on medicines developed by Chinese biotechs this year, underscoring how Big Pharma is increasingly reliant on China ...

An analysis reveals a spike in pro-Russian disinformation networks surrounding the attempt to oust the European Commission ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

WASHINGTON] Crypto companies and advocates of digital assets boosted their lobbying this year to ensure passage of landmark ...

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who could benefit.